While the founder of Woebot Health says that the app is not intended to replace human therapists, for the majority of the world who cannot locate an available psychologist or afford one once found, Woebot aims to offer a “radically accessible” option for mental health care.

Neuroelectrics Inc. garnered $17.5 million in a series A fundraising round led by the Morningside Group of Hong Kong. The Cambridge, Mass. and Barcelona-based brain stimulation company plans to use the funds primarily to advance its pivotal trial of the Starstim system in refractory focal epilepsy and its at-home feasibility study in refractory major depressive disorder and related infrastructure, Neuroelectrics co-founder and CEO Ana Maiques told BioWorld. Supportive infrastructures for the trials include brain modeling, the platform for remote montage delivery, and clinical and regulatory resources.

Eliem Therapeutics Inc. is old-fashioned in the useful ways. The company is going after extremely large indications, including chronic pain and major depression. “We’re really passionate about these large markets,” Eliem President and CEO Bob Azelby told BioWorld. “These patients live in the shadows… There’s so many people suffering.”

There is a fundamental disconnect between how rapidly antidepressants act molecularly, and how slowly they act clinically.

A study by researchers at Nanjing University has demonstrated that in mice, depression-like phenotypes induced by paternal stress can be inherited by the offspring through a causal role of microRNAs in the father's sperm.

A genome-wide look at variants in RNA-binding proteins has revealed that such variants were disproportionately linked to the risk of multiple psychiatric disorders.

DUBLIN – A re-evaluation of psychedelic drugs as potential therapies for major depressive disorder, anxiety, post-traumatic stress disorder and other neuropsychiatric conditions has been underway for some time, but this broad effort gained further momentum during 2020, as commercial firms started to raise money at the level needed to enable the field to start moving from small-scale academic studies to the kind of industry-scale trials that will be needed to convince regulators, patients and physicians that these molecules could become viable treatment options.

Using in vivo imaging technology, investigators at the University of Utah and the University of Padua have identified a new signaling mechanism for glutamate that was linked to the onset of spreading depression or spreading depolarization, a neuronal activity pattern that plays a role in multiple neurological disease states. In mouse models of migraine, glutamate, which is the major excitatory neurotransmitter of the brain, was released in what the authors called "plumes" or puffs.

Using in vivo imaging technology, investigators at the University of Utah and the University of Padua have identified a new signaling mechanism for glutamate that was linked to the onset of spreading depression or spreading depolarization, a neuronal activity pattern that plays a role in multiple neurological disease states.